Sanatorio Parque - Rosario
Sanatorio Parque - Rosario
Boulevard Oroño 860, Rosario, Santa Fe
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Miguel Angel Escudero
Silvina Mannarino
Gastón Lucas Martinengo
Juan Ausili
Open studies
Lung cancer
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations - TROPION-Lung08 - AstraZenecaSee more
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) - TROPION-Lung07 - AstraZenecaSee more
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) - CodeBreaK 202 - AmgenSee more
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - MK-2870-019 - Merck Sharp & Dohme LLCSee more
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) - MK-1084-004 - Merck Sharp & Dohme LLCSee more
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] - MK-2870-023 - Merck Sharp & Dohme LLCSee more
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer - Krascendo 1 - Hoffmann-La RocheSee more
A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer - Be6A Lung-01 - Seagen Inc.See more
Breast Cancer
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) - lidERA - Hoffmann-La RocheSee more
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) - TAXIS - University Hospital, Basel, SwitzerlandSee more
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) - PionERA - Hoffmann-La RocheSee more
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) - MK-2870-012 - Merck Sharp & Dohme LLCSee more
Acute Coronary Syndrome
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome - LIBREXIA-ACS - Janssen Research & Development, LLCSee more
Leukemia
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Non-Hodgkin Lymphoma
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). - BELLWAVE-010 - Merck Sharp & Dohme LLCSee more
Pulmonary hypertension
A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients - APD811-301 - United TherapeuticsSee more
